Navigation Links
Romark Laboratories Awarded Contract For Late-Stage Development Of New Influenza Drug
Date:2/28/2013

TAMPA, Fla., Feb. 28, 2013 /PRNewswire/ -- Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the advanced development of NT-300 (nitazoxanide) as a treatment of acute uncomplicated influenza. The value of the cost plus fixed-fee contract is up to $44 million.

(Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO

The contract will be administered through the Biomedical Advanced Research and Development Authority (BARDA).  BARDA, an agency within the Office of the Assistant Secretary for Preparedness and Response, supports advanced development of and procures medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. 

"There is a pressing need for new drugs to treat influenza," said Jean-Francois Rossignol , M.D., Ph.D., Chairman and Chief Science Officer of Romark.  "BARDA plays an important role in the advanced development of new countermeasures for public health threats such as pandemic influenza, and we are pleased to have the opportunity to work with them."

The contract award followed BARDA's solicitation of proposals for development of antiviral therapeutics with new mechanisms of action against influenza. Areas of interest to BARDA addressed by Romark's development plan include a novel mechanism of action, targeting of host factors, potential for broad spectrum antiviral activity and combination therapeutic approaches using an influenza antiviral and a host modulating therapeutic. Importantly, NT-300 is administered orally, and it is being proposed for treatment of seasonal as well as pandemic influenza.

Currently, there are only two c
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunotech Laboratories Receives $2M Funding Approval To Begin European Clinical Trials Testing For Companys Patented "IPF" HIV-AIDS Medicines
2. Breaking News: Video Interview With Harry Zhabilov of Immunotech Laboratories Inc.
3. Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Companys Growth and International Expansion Plan
4. Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS
5. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
6. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
7. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
8. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
9. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
10. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
11. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... HOUSTON, TX and VANCOUVER , ... the "Company") (TSX-V: EPI) announced today that its common shares ... Capital Market ("NASDAQ") under the symbol "EPIX". ESSA ... Company will retain its listing on the TSX Venture Exchange ... the listing of the common shares on the NASDAQ, each ...
(Date:7/2/2015)... , July 2, 2015  Fort Lauderdale-based ... pleased to announce that its Consumer Group completed ... to Kerry Group plc (ISE: KRZ) ("Kerry"), one ... and nutrition systems, as well as functional ingredients ... pharmaceutical markets. Farlie Turner served as the exclusive ...
(Date:7/2/2015)... July 2, 2015 Roche,s Bloodhound technology ... market segment in hematology testing, according to Kalorama ... recent unveiling of its Bloodhound digital cell imaging ... m 511 hematology analyzer – is notable ... enjoyed by current leader CellaVision, but also compete ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first ... and athletic trainers. Their significant popularity has inspired four new, fun shades including: ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com recently ... passion for social fitness. Built to function as a lifestyle community, Active Bunch allows ... the opportunity to network, meet, and participate in discussions or group events. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... company , announced today that it has reached an agreement to acquire ... CleanItSupply.com the largest distributor of Rubbermaid Commercial Products on the web today. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Octo Consulting Group, (Octo), a ... government, has announced they are among nine contractors awarded the U.S. Securities and ... contract not to exceed $250 million. , To achieve the goals of ...
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3
... Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that Richard Van der Jagt, M.D. of ... the 2009 Pan Pacific Lymphoma Conference on Monday, June 22, 2009. The conference will be ... Hawaii. , , , ... 2009 Pan Pacific Lymphoma Conference, ...
... , , , President Obama Calls For Health ... 15 The American Medical Association warmly welcomed U.S. ... Like the president, the AMA is committed to health reform this ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) , ...
... MBA, FACPE, Ameritox,s Senior Vice President and Chief Medical Officer, ... for the American College of Physician Executives (ACPE), a national ... , Dr. Leider became an ACPE member 20 years ... College for 13 years teaching courses on improving the quality ...
... 16, 2009 at 9:00 a.m. Eastern Time , , ... ALXA ) announced today that it has exercised ... Allegro. The purchase of Symphony Allegro, which is subject ... 2009. , , Alexza and Symphony Capital Partners, LP ...
... June 15 Citing evidence that even a very low level ... the Council of State and Territorial Epidemiologists (CSTE) is recommending a ... adults. In a vote at the CSTE annual conference in Buffalo, ... 10 ug/dl or more in adults as "elevated" -- the same ...
... 15, 2009 (BRONX, NY) In a study ... researchers from Albert Einstein College of Medicine of Yeshiva ... HIV-positive individuals are most likely to develop deadly fungal ... of meningitis affects more than 900,000 HIV-infected people globallymost ...
Cached Medicine News:Health News:President Obama Receives Warm Welcome from AMA Physicians 2Health News:Ameritox(R) CMO Elected Chairman of the American College of Physician Executives Board 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 3Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 4Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 5Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 6Health News:CSTE Leads Effort to Improve Blood Lead Reporting 2Health News:CSTE Leads Effort to Improve Blood Lead Reporting 3Health News:Predicting fatal fungal infections 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
... Clinicians are demanding smaller, higher performing ... clinical and operational challenges. The new ... powerful architecture for superb High Definition ... and ease-of-use; and a versatile suite ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... InfinixTM CF-i/SP brings revolutionary flexibility to ... enables operators to move the C-arm ... to obtain the optimal angle for ... features an 8-inch cardiac flat panel ...
Medicine Products: